Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Recipient : Honeywell
Deal Size : Undisclosed
Deal Type : Agreement
Honeywell to Power DevPro’s Next-generation Low-Emission Respiratory Inhaler
Details : The agreement will support development of DP007 (albuterol) inhalation aerosol indicated for bronchospasm in patients 4 years of age & older with reversible obstructive airway disease.
Product Name : DP007
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 10, 2024
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Recipient : Honeywell
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Early feasibility studies on climate-friendly albuterol inhaler completed
Details : DP007 inhalation aerosol is a beta2-adrenergic agonist indicated for the treatment of bronchospasm in patients 4 years of age & older with reversible obstructive airway disease.
Product Name : DP007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 11, 2024
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable